Cargando…

2398. Effect of Eosinopenia and Binary Toxin on Clostridioides difficile Infection Clinical Outcomes

BACKGROUND: The ability of Clostridioides difficile to cause clinical disease in humans is dependent on toxin production. Significantly fewer eosinophils are seen in the peripheral blood of mice infected with a binary toxin positive (CDT+) C. difficile strain. Furthermore, the presence of CDT and eo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carlson, Travis J, Endres, Bradley T, Le Pham, Julie, Gonzales-Luna, Anne J, Alnezary, Faris S, Nebo, Kimberly, Miranda, Julie, Begum, Khurshida, Alam, M Jahangir, Garey, Kevin W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810537/ http://dx.doi.org/10.1093/ofid/ofz360.2076

Ejemplares similares

Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

1197. Inhibitory Effect of Ursodeoxycholic Acid on Clostridioides difficile Growth
por: Alnezary, Faris, et al.
Publicado: (2020)

784. A Novel Method to Assess Virulence of Clostridioides difficile: Focus on C. difficile Ribotype 106
por: Almutairi, Masaad, et al.
Publicado: (2020)

Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

In vitro activity of eravacycline against common ribotypes of Clostridioides difficile
por: Bassères, Eugénie, et al.
Publicado: (2020)

In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile
por: Begum, Khurshida, et al.
Publicado: (2020)

2581. An Invertebrate Model to Study Gut Microbiome Dysbiosis
por: Alnezary, Faris S, et al.
Publicado: (2019)

PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255
por: Gonzales-Luna, Anne J., et al.
Publicado: (2020)

682. Novel rpoB mutations and trends in clinical Clostridioides difficile isolates with reduced fidaxomicin susceptibility
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

2391. Increased Risk of Systemic Infections with Multidrug-Resistant Organisms in Patients with Severe Clostridioides difficile Infection
por: Dotson, Kierra M, et al.
Publicado: (2019)

Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection
por: Gonzales-Luna, Anne J, et al.
Publicado: (2021)

2410. Molecular Characteristics of Environmental Clostridioides difficile From a Large Texas Hospital
por: Begum, Khurshida, et al.
Publicado: (2019)

802. Proton Pump Inhibitors Increase Clostridioides difficile Disease Severity Controlling for Infecting Strains
por: Fallatah, Saad, et al.
Publicado: (2020)

2378. Corticosteroid Use Prevents Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use Among Hospitalized Patients
por: Carlson, Travis J, et al.
Publicado: (2019)

Emerging Options for the Prevention and Management of Clostridioides difficile Infection
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

710. Increased Clinical Failure Rates Associated with Reduced Metronidazole Susceptibility in Clostridioides difficile
por: Gonzales-Luna, Anne, et al.
Publicado: (2018)

Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection
por: McPherson, Jacob, et al.
Publicado: (2022)

688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile
por: Basseres, Eugenie, et al.
Publicado: (2019)

Corticosteroids Do Not Increase the Likelihood of Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use
por: Carlson, Travis J, et al.
Publicado: (2021)

2402. Clinical Outcomes Associated with an Emerging Clostridioides difficile Ribotype 255 in Texas
por: Gonzales-Luna, Anne J, et al.
Publicado: (2019)

701. An Open-label Phase 2a Study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS) Antibiotic, for Patients with Clostridioides difficile Infection
por: Garey, Kevin W, et al.
Publicado: (2021)

Comparison of Risk Stratification Approaches to Identify Patients with Clostridioides difficile Infection at Risk for Multidrug-Resistant Organism Gut Microbiota Colonization
por: Zasowski, Evan J., et al.
Publicado: (2023)

795. Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Guideline on the Classification of Clostridioides difficile Infection Severity
por: Carlson, Travis J, et al.
Publicado: (2020)

Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

741. Antifungal Resistant Candida glabrata Are Most Commonly Colonized in Clostridioides difficile Infection (CDI) Patient Guts in Texas
por: Begum, Khurshida, et al.
Publicado: (2020)

Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains
por: Endres, Bradley T, et al.
Publicado: (2019)

An Update on Clostridioides difficile Binary Toxin
por: Martínez-Meléndez, Adrián, et al.
Publicado: (2022)

Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial( )
por: Garey, Kevin W, et al.
Publicado: (2022)

510. First Environmental Investigation of Toxigenic Clostridium difficile Strains in Texas Hospitals
por: Alam, M Jahangir, et al.
Publicado: (2018)

1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile
por: Mason, Clive, et al.
Publicado: (2021)

2580. Serial Microbiome Analysis in a Patient with Multiple Failed Fecal Microbiome Transplantations
por: Gonzales-Luna, Anne J, et al.
Publicado: (2019)

471. Prevalence and Characteristics of Clostridioides difficile Infection in Bangladesh
por: Sofjan, Amelia K, et al.
Publicado: (2018)

First Environmental Investigation of Toxigenic Clostridium difficile at a Large Hospital in Bangladesh
por: Alam, M Jahangir, et al.
Publicado: (2017)

LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor
por: Garey, Kevin W, et al.
Publicado: (2019)

Diversity of binary toxin positive Clostridioides difficile in Korea
por: Kim, Jieun, et al.
Publicado: (2023)

18. Global Surveillance of Clostridioides difficile Demonstrates High Prevalence in Non-Healthcare Settings
por: Jo, Jinhee, et al.
Publicado: (2021)

Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review
por: Eubank, Taryn A., et al.
Publicado: (2022)

The prognostic value of toxin B and binary toxin in Clostridioides difficile infection
por: López-Cárdenas, Salvador, et al.
Publicado: (2021)

The Importance of Therapeutically Targeting the Binary Toxin from Clostridioides difficile
por: Abeyawardhane, Dinendra L., et al.
Publicado: (2021)

Binary Toxin Expression by Clostridioides difficile Is Associated With Worse Disease
por: Young, Mary K, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5f9kt1eio0ojfmh6j380404dbn